Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
On December 22, 2025, the FDA approved Novo Nordisk's once-daily oral semaglutide (Wegovy pill, 25 mg) for chronic weight management and cardiovascular risk reduction (FDA / Novo Nordisk, 2025)
You should not take this medication if you have: A personal or family history of Medullary Thyroid Carcinoma (MTC)
See full terms at WegovyTerms.com and NovoCarePharmacyTerms.com
Your doctor must document the diabetes diagnosis with appropriate lab work (typically HbA1c levels) and show that first-line diabetes medications were tried first
The results reported by satisfied Brello users, including one user reporting 112 pounds of weight loss, suggest effective outcomes are achievable
US$ 26.25
US$ 27.00
US$ 21.98
US$ 21.23
US$ 27.04
US$ 22.38
US$ 20.18
US$ 20.76
US$ 26.98
US$ 24.59
US$ 29.55
